Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin’s lymphoma: the survival gain improves as more mature follow-up data become available.
Autori
Andrea Messori, Laura Bartoli, Daniele Mengato, Marco Chiumente
Rivista
Eur J Hosp Pharm
Topic
Analisi statistiche e metanalisi
Impact Factor
0,892
Abstract
non disponibile
Link PubMed del paper
https://pubmed.ncbi.nlm.nih.